Exploring the potential of asparagine restriction in solid cancer treatment: recent discoveries, therapeutic implications, and challenges

Fontes, Marina Gabriel; Silva, Carolina; Roldán, William Henry; Monteiro, Gisele

doi:10.1007/s12032-024-02424-3

Med Oncol

2024

DOI: 10.1007/s12032-024-02424-3

|View full text |Cite

Exploring the potential of asparagine restriction in solid cancer treatment: recent discoveries, therapeutic implications, and challenges

Marina Gabriel Fontes,

Carolina Silva,

William Henry Roldán

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 97 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Asparagine: A key metabolic junction in targeted tumor therapy

Wang,

Gong,

Xiong

et al. 2024

Pharmacological Research

View full text Add to dashboard Cite

Asparagine: A key metabolic junction in targeted tumor therapy

Wang,

Gong,

Xiong

et al. 2024

Pharmacological Research

View full text Add to dashboard Cite

Unveiling the Promise: Navigating Clinical Trials 1978–2024 for PDAC

Dominguez,

Perz,

et al. 2024

Cancers

View full text Add to dashboard Cite

Despite many decades of research, pancreatic ductal adenocarcinoma (PDAC) remains one of the most difficult cancers to diagnose and treat effectively. Although there have been improvements in the 5-year overall survival rate, it is still very low at 12.5%. The limited efficacy of current therapies, even when PDAC is detected early, underscores the aggressive nature of the disease and the urgent need for more effective treatments. Clinical management of PDAC still relies heavily on a limited repertoire of therapeutic interventions, highlighting a significant gap between research efforts and available treatments. Over 4300 clinical trials have been or are currently investigating different treatment modalities and diagnostic strategies for PDAC, including targeted therapies, immunotherapies, and precision medicine approaches. These trials aim to develop more effective treatments and improve early detection methods through advanced imaging techniques and blood-based biomarkers. This review seeks to categorize and analyze PDAC-related clinical trials across various dimensions to understand why so few chemotherapeutic options are available to patients despite the numerous trials being conducted. This review aims to provide a comprehensive and nuanced understanding of the landscape of PDAC-related clinical trials, with the overarching goal of identifying opportunities to accelerate progress in drug development and improve patient outcomes in the fight against this devastating disease.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Exploring the potential of asparagine restriction in solid cancer treatment: recent discoveries, therapeutic implications, and challenges

Cited by 2 publications

References 97 publications

Asparagine: A key metabolic junction in targeted tumor therapy

Asparagine: A key metabolic junction in targeted tumor therapy

Unveiling the Promise: Navigating Clinical Trials 1978–2024 for PDAC

Contact Info

Product

Resources

About